The Aberrant Behavior Checklist for Fragile X Syndrome: A Qualitative Clinician Evaluation of Content Validity

<b><i>Objective:</i></b> The current intense period of drug development for fragile X syndrome (FXS) and other neurodevelopmental disorders (NDDs) indications has highlighted the importance of behavioral outcome measures with strong psychometric properties and specifically content validity. The Aberrant Behavior Checklist-Community Edition (ABC-C), which has successfully been applied to autism spectrum disorder drug trials, has been revised for FXS (ABC<sub>FX</sub>) and is widely used for both clinical and research purposes. Despite its strong psychometric validation, the ABC<sub>FX</sub> and its parent measure have not been subjected to qualitative content validity evaluations. The present study intended to fill this gap. <b><i>Methods:</i></b> Using two surveys administered sequentially and developed with guidance and review from the Food and Drug Administration (FDA), we asked 10 clinicians experienced in FXS and related NDDs to determine the adequacy of the ABC<sub>FX</sub> for assessing its behavioral constructs, its relevance to FXS, and its potential for detecting response to interventions. Various descriptive statistic parameters and <i>ad hoc</i> metrics were used to analyze categorical and Likert-like scale responses. <b><i>Results:</i></b> Experts considered that most items and all six ABC<sub>FX</sub> subscales indeed evaluated their explicit or implicit behavioral constructs. However, item and subscale specificity were relatively low (∼25%-30%). Relevance of items of the Hyperactivity subscale was relatively high while low for many items of the Socially Unresponsive/Lethargic subscale. These items were also considered of low responsiveness potential. Irritability, Hyperactivity, Stereotypy, and Social Avoidance were the subscales with the strongest profiles, although the experts estimated that Stereotypy items may not be that responsive to treatment. A novel Anxiety construct, representing mainly recently reported observable behaviors, contributed mainly by Irritability items, emerged as a potential measure. <b><i>Conclusions:</i></b> The present study demonstrated the overall adequacy of the ABC<sub>FX</sub> for its behavioral constructs, its relevance to FXS, and its potential for detecting response to treatment. It also showed that anxiety, a distinctive feature of FXS and other genetic NDDs, can also be measured by the ABC<sub>FX</sub>. These findings can help with the implementation and interpretation of the ABC<sub>FX</sub>, as well as with potential improvements to the measure in FXS and other NDDs.

Authors

Institutions

Publication Details

Journal
Journal of Child and Adolescent Psychopharmacology
Published
2025-02-06
DOI
https://doi.org/10.1089/cap.2024.0147
Citations
2
Primary Topic
Genetics and Neurodevelopmental Disorders
Type
article
Field-Weighted Citation Impact
3.63
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Aberrant Behavior Checklist for Fragile X Syndrome: A Qualitative Clinician Evaluation of Content Validity

Lindsay M. Oberman, Craig A. Erickson, David Hessl, Elizabeth Berry‐Kravis et al.
2 citations
Journal of Child and Adolescent Psychopharmacology
Genetics and Neurodevelopmental Disorders
3.63
article

The Aberrant Behavior Checklist for Fragile X Syndrome: A Qualitative Clinician Evaluation of Content Validity

Lindsay M. Oberman, Craig A. Erickson, David Hessl, Elizabeth Berry‐Kravis, Nicole Tartaglia, Holly K. Harris, Audrey Thurm, Reymundo Lozano, Dejan B. Budimirovic, Randi J. Hagerman, Walter E. Kaufmann, James Tran
article en
2 citations

Abstract

<b><i>Objective:</i></b> The current intense period of drug development for fragile X syndrome (FXS) and other neurodevelopmental disorders (NDDs) indications has highlighted the importance of behavioral outcome measures with strong psychometric properties and specifically content validity. The Aberrant Behavior Checklist-Community Edition (ABC-C), which has successfully been applied to autism spectrum disorder drug trials, has been revised for FXS (ABC<sub>FX</sub>) and is widely used for both clinical and research purposes. Despite its strong psychometric validation, the ABC<sub>FX</sub> and its parent measure have not been subjected to qualitative content validity evaluations. The present study intended to fill this gap. <b><i>Methods:</i></b> Using two surveys administered sequentially and developed with guidance and review from the Food and Drug Administration (FDA), we asked 10 clinicians experienced in FXS and related NDDs to determine the adequacy of the ABC<sub>FX</sub> for assessing its behavioral constructs, its relevance to FXS, and its potential for detecting response to interventions. Various descriptive statistic parameters and <i>ad hoc</i> metrics were used to analyze categorical and Likert-like scale responses. <b><i>Results:</i></b> Experts considered that most items and all six ABC<sub>FX</sub> subscales indeed evaluated their explicit or implicit behavioral constructs. However, item and subscale specificity were relatively low (∼25%-30%). Relevance of items of the Hyperactivity subscale was relatively high while low for many items of the Socially Unresponsive/Lethargic subscale. These items were also considered of low responsiveness potential. Irritability, Hyperactivity, Stereotypy, and Social Avoidance were the subscales with the strongest profiles, although the experts estimated that Stereotypy items may not be that responsive to treatment. A novel Anxiety construct, representing mainly recently reported observable behaviors, contributed mainly by Irritability items, emerged as a potential measure. <b><i>Conclusions:</i></b> The present study demonstrated the overall adequacy of the ABC<sub>FX</sub> for its behavioral constructs, its relevance to FXS, and its potential for detecting response to treatment. It also showed that anxiety, a distinctive feature of FXS and other genetic NDDs, can also be measured by the ABC<sub>FX</sub>. These findings can help with the implementation and interpretation of the ABC<sub>FX</sub>, as well as with potential improvements to the measure in FXS and other NDDs.

Journal of Child and Adolescent PsychopharmacologyVol. 35(7)
Cincinnati Children's Hospital Medical Center (US), Rush University Medical Center (US), Boston Children's Hospital (US), Kennedy Krieger Institute (US), National Institutes of Health (US), Johns Hopkins University (US), Emory University (US), Mount Sinai Hospital (US), Texas Children's Hospital (US), National Institute of Mental Health (US), University of California Davis Medical Center (US), University of California, Davis (US), University of Colorado Denver (US)
Openalex Percentile: Top 9%
Genetics and Neurodevelopmental Disorders
3.63
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.